Tabimorelin

Drug Profile

Tabimorelin

Alternative Names: NN 703; NNC 26-0703

Latest Information Update: 21 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Peptides
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Somatotropin deficiency

Most Recent Events

  • 16 Jun 2003 A study has been added to the Endocrine Disorders therapeutic trials section
  • 11 Apr 2003 A clinical study has been added to the drug interactions section
  • 14 Aug 2001 A clinical study has been added to the Endocrine Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top